bluebird bio
NEWS
It was a particularly busy week in clinical trial news, largely because of the American Society of Hematology Annual Meeting. Here’s a look.
Similar to the Biotech Bay list, BioSpace takes a look at the top 10 2019 Life Sciences Ideal Employer Report’s for Genetown.
For BioSpace’s recent Ideal Employer report, life sciences professionals weighed in on the topic.
The deal will last three years, with a top priority to develop a gene therapy for hemophilia A.
In the latest Ideal Employer Survey, BioSpace readers chimed in their thoughts on which companies across the biotech and biopharma industries were doing the most interesting and meaningful work.
According to the second biennial 2019 Life Sciences Ideal Employer Report by BioSpace, the top three most important attributes cited by life sciences professionals around the world are the opportunity to do interesting and meaningful work, a competitive salary and health benefits.
There are high hopes for more M&A in the industry for the remainder of the year. Here’s a look at the 10 top takeover targets.
Last week there were quite a few clinical trials whose data were presented. Many were at the American Diabetes Association 79th Scientific Sessions, while others were presented at separate meetings or independently. Here’s a look.
Cambridge, Mass.-based bluebird bio released updated results from three clinical trials of its LentiGlobin gene therapy for transfusion-dependent Beta-thalassemia.
JOBS
IN THE PRESS
bluebird bio, Inc. (NASDAQ: BLUE) today announced that the company will host a live webcast to review new data presented at the European Hematology Association (EHA) Annual Meeting on Friday, June 12 at 8:00 am ET. Investors may listen to the call on June 12, 2020 at 8:00 am ET by dialing (844) 825-4408 from locations in the United States or +1 (315) 625-3227 from outside the United States. Please refer to conferenc
bluebird bio, Inc. announced the pricing of an underwritten public offering of 9,090,910 shares of its common stock at a public offering price of $55.00 per share, before underwriting discounts.
bluebird bio, Inc. announced that it has commenced an underwritten public offering of $400 million of its common stock. bluebird bio also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent of the shares of common stock offered in the public offering.
bluebird bio to Present Data from Its Gene and Cell Therapy Programs During the Virtual Edition of the 25 th European Hematology Association Annual Congress Presentation of new and updated results from ongoing Phase 1/2 HGB-206 study of LentiGlobin for sickle cell disease will include additional patients treated in the study New and updated data, including analysis of healthy red blood cell production in patients with transfusion-dependent β-thalassemia
Bristol Myers Squibb and bluebird bio, Inc. announced updated results from the pivotal, Phase 2 KarMMa study evaluating the efficacy and safety of the companies’ investigational B-cell maturation antigen -directed chimeric antigen receptor T cell immunotherapy, idecabtagene vicleucel, in patients with relapsed and refractory multiple myeloma.
Bristol Myers Squibb to host an investor call today at 8:00 a.m. EDT bluebird bio to host an investor call today at 8:45 a.m. EDT
Bristol Myers Squibb to buy out its ex-U.S. milestone and royalty obligations to bluebird bio for $200 million – - Bristol Myers Squibb assumes responsibility for vector manufacturing in ex-US territories – - bluebird to hold conference call and webcast today, May 11, 2020 at 8:00AM ET – CAMBRIDGE, Mass.--( BUSINESS WIRE )-- bluebird bio, Inc. (NASDAQ: BLUE) today announced that it has amended its existing co-promotion/co-development a
Alignment with FDA on an accelerated regulatory path for LentiGlobin for sickle cell disease based on HGB-206 study with targeted submission in 2H 2021
Hitachi Chemical Advanced Therapeutics Solutions, LLC and apceth Biopharma GmbH, both subsidiaries of Hitachi Chemical Co., Ltd. announced that they have expanded their relationship with bluebird bio with long-term development and manufacturing services agreements for clinical and commercial supply for multiple therapies, including:.
Virtual oral presentation will include updated efficacy and safety data from pivotal Phase 2 KarMMa study of ide-cel- -Biologics License Application under review with U.S. Food and Drug Administration (FDA)- CAMBRIDGE, Mass.--( BUSINESS WIRE )-- bluebird bio, Inc. (Nasdaq: BLUE) announced today that updated results from the pivotal Phase 2 KarMMa study evaluating the efficacy and safety of idecabtagene vicleucel (ide-cel; bb2121), an invest